Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

NEWS ABOUT: GlaxoSmithKline

Stories 21 - 32 | << Prev 

Switch to grid view »

Beefed-Up R&D Slows Drug Approval

Just 19 new meds cleared FDA in 2007

(Newser) - The FDA approved only 19 new drugs in 2007, the lowest total in 24 years. Bloomberg takes a look at the reasons. Some drug companies accuse the FDA of setting the bar higher for drug approvals, a charge the agency denies. Many, however, say the issue lies with big pharma... More »

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic... More »

Tamiflu Will Carry Stronger Warning Labels

Maker will beef up language on possible psychiatric side effects

(Newser) - The maker of flu drug Tamiflu said today it will accept recommendations by a government panel that it revise printed warnings about the medication's side effects. Labels already warn of possible psychiatric reactions, but the panel recommended noting that some people have died, the AP reports. Drugmaker Roche says flu... More »

Diabetes Drug Given Strictest Warning Label

FDA's 'black box' adds risk of heart attack to concerns on Avandia

(Newser) - The FDA has applied its harshest warning to the diabetes drug Avandia, declaring the product potentially increases risk of heart attacks. Now marked with a “black box” warning, GlaxoSmithKline’s drug will stay on the market pending a continuing “safety assessment,” the Wall Street Journal reports; FDA... More »

Court Blocks New Patent Rules

Judge grants injunction for drug giant GlaxoSmithKline

(Newser) - A Federal judge has blocked the US Patent and Trademark Office from implementing tough new patent rules with a temporary injunction in a suit brought by GlaxoSmithKline. The Wall Street Journal reports the new rules would have limited the number of times patent holders may make minor changes to existing... More »

FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link

(Newser) - An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs. More »

Dow Sinks Further on Credit Jitters

GDP report, earnings, can't stave off 208.10 point slide

(Newser) - Stocks tumbled more than 200 points for the second day in a row, on fears that small-cap securities might be especially hard hit by a possible collapse in certain financial services. The Dow was down 208.10 to 13265.47, despite a report that the GDP grew faster this quarter... More »

Controversy Rages Over Diabetes Drug's Heart Risks

FDA official says superiors ordered her to back off serious warning

(Newser) - Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting... More »

Glaxo Stems Stock Slide Over Avandia

Medical chief rebuts findings on heart risks; claims comparable to other drugs

(Newser) - Glaxo shares pulled out of a tailspin after the pharma giant defended its second biggest selling drug, Avandia, against claims that it triggers heart attacks.  A sharply worded letter from the company's chief medical officer on the website of medical journal The Lancet pointed out that the increased incidence... More »

FDA Warned of Avandia Risks Years Ago

Doctor alerted agency to cardiovascular concerns in 2000

(Newser) - A diabetes doctor warned the FDA of heart risks posed by the diabetes drug Avandia seven years ago, the New York Times reports. The same concerns raised by Dr. John Buse in a 2000 letter were reiterated in a study published by cardiologist Steven Nissen this week. More »

Drug Company Nemesis Strikes Again

Crusading cardiologist took on Vioxx, now Avandia, for heart risks

(Newser) - The doctor who helped to raise concerns about the painkiller Vioxx is back—with the study released earlier this week linking the same company's popular diabetes drug, Avandia, to higher risk of heart attacks. The Wall Street Journal looks at 58-year-old cardiologist Steven Nissen's role in identifying and publicizing drug... More »

Diabetes Drug Ups Heart Risk

New study documents dangers of Avandia, but company nixes recall

(Newser) - A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found. More »

Stories 21 - 32 | << Prev 
NEWS FROM OUR PARTNERS
Other Sites We Like:   24/7 Wall St.   |   Betty Confidential   |   BuzzFeed   |   Cracked   |   Fark   |   Timelines   |   The Frisky   |   Geek Sugar   |   NewsOne